Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 126 Matches

Dihydroartemisinin (DHA)

Model Files Publication

Brand Name(s) include: D-Artepp, Artekin, Diphos, TimeQuin, Eurartesim, Duocotecxin

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2) Note: Kp scalar used
Route of Elimination	UGT1A9 (50%); UGT2B7(50%)
Perpetrator DDI	CYP1A2 Inhibitor
Validation	Four clinical studies describing single dose exposure of DHA were used to verify the PBPK model. 100% of studies were within 2-fold, of which 75% were within 1.5-fold. Thus, the model performance was deemed acceptable.
Limitations	The model does not account for the differences in plasma fraction unbound observed in patients compared to healthy volunteers. Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.
Updates in V19	Updated in vitro data Propranolol Papp: 30 cm/s x 106 Converted model to full PBPK with Vss predicted through Method 2 Updated retrograde clearance

Search Score: 1

Nevirapine

Model Files Publication

Brand Name: Viramune

Disease: HIV

Drug Class: non-nucleoside reverse transcriptase inhibitor

Version: 21

Date Updated: March 2024

The model at-a-glance

Absorption Model	First order
Volume of Distribution Details	Full PBPK (Method 2)
Route of Elimination	CYP2B6 = 35%; CYP2D6 = 12%; CYP3A4 = 45%; Additional HLM = 5%; Renal Clearance 3% at steady state
Perpetrator DDI	CYP2B6 Induction CYP3A4 Induction
Validation	The refined model was able to recover clinically observed concentration-time profiles of nevirapine following single and multiple dosing. Four clinical DDI studies where nevirapine was administered with either fluconazole, rifampin, or itraconazole were used to verify the PBPK model of nevirapine as a victim. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.25-fold. Two clinical DDI studies where nevirapine was administered with either itraconazole or quinidine were used to verify the PBPK model of nevirapine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.5-fold.
Limitations	There are no DDI studies where nevirapine was given as a single dose and so it is not possible to verify fm of CYP2B6 and CYP3A4 for a single dose. There is no independent DDI study to verify induction of CYP2B6.

Search Score: 1

Adefovir_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Adefovir compound in healthy volunteers. Hsueh et al evaluating the effect of renal impairment on PK of OAT substrates. 30/07/2019: The Adefovir PBPK model was submitted with the setting as Hepatocyte Clearance input in the WOMC option. To allow DDI simulations the file should be set up in the Enzyme Kinetics option by moving the Hepatocyte clearance value into the Additional Clearance (Liver) subtab under the Enzyme Kinetics section.

Search Score: 1

Dabigatran&DabigatranEtexilate_V17R1_UniversityOfTsukuba_20190204

Model Files Publication

Dabigatran etexilate and dabigatran compound files. Assessment of potential DDIs with P-gp inhibitors in renal impairment populations. https://www.ncbi.nlm.nih.gov/pubmed/30659778 https://doi.org/10.1002/psp4.12382

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Dihydroartemisinin (DHA)

The model at-a-glance

Nevirapine

The model at-a-glance

Adefovir_V15R1_USFDA_20170810

Dabigatran&DabigatranEtexilate_V17R1_UniversityOfTsukuba_20190204

Your Privacy